In early December 2019,the city of Wuhan,China,reported an outbreak of coronavirus disease(COVID-19),caused by a novel severe acute respiratory syndrome coronavirus-2(SARS-CoV-2).On January 30,2020,the World Health Or...
详细信息
In early December 2019,the city of Wuhan,China,reported an outbreak of coronavirus disease(COVID-19),caused by a novel severe acute respiratory syndrome coronavirus-2(SARS-CoV-2).On January 30,2020,the World Health Organization(WHO)declared the outbreak a global pandemic *** the face of the COVID-19 pandemic,the most important step has been the effective diagnosis and monitoring of infected *** COVID-19 using Machine Learning(ML)technologies can help the health care unit through assistive diagnostic suggestions,which can reduce the health unit's burden to a certain *** paper investigates the possibilities of ML techniques in identifying/detecting COVID-19 patients including both conventional and exploring from chest X-ray images the effect of viral *** approach includes preprocessing,feature extraction,and ***,the features are extracted using the Histogram of Oriented(HOG)and Local Binary Pattern(LBP)feature ***,for the extracted features classification,six ML models of Support Vector Machine(SVM)and K-Nearest Neighbor(KNN)is *** results show that the diagnostic accuracy of random forest classifier(RFC)on extracted HOG plusLBP features is as high as 94%followed by SVM at 93%.The sensitivity of the K-nearest neighbour model has reached an accuracy of 88%.Overall,the predicted approach has shown higher classification accuracy and effective diagnostic *** is a highly useful tool for clinical practitioners and radiologists to help them in diagnosing and tracking the cases of COVID-19.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide adequate glycemic control, weight reduction, low risk of hypoglycemia, and CV risk reduction. Their usage for type 2 DM (T2DM) is recommended mainly when hy...
详细信息
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide adequate glycemic control, weight reduction, low risk of hypoglycemia, and CV risk reduction. Their usage for type 2 DM (T2DM) is recommended mainly when hypoglycemia or weight gain should be considered, also, whenever initial therapy is failed. There are many recent updates in the treatment paradigm of T2DM. There are many types of GLP-1RAs, with a knowledge gap regarding switching between the different types. A Saudi task force gathered to develop an explicit, evidence-based consensus for switching between GLP-1RAs, when, why, and how? This article contains the expert panel’s recommendations as a contribution to complement the knowledge gap in this area from the national perspective. As an alternative to intensifying therapy, switching from one GLP-1RA to another has various advantages. Improvements in glycemic control, weight loss, adherence, and medications with established cardiovascular benefits are among them. Also, switching needs to be individualized upon many discussed factors like the dose of the previous GLP1-RA and gastrointestinal adverse effects. Discussion with patients about the why and how to switch is critical.
暂无评论